MedPharm, Ltd

About MedPharm, Ltd

MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm are experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective, and industry-leading performance testing models. Well-established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognized for their scientific rigor by regulators and investors. MedPharm has fully established Centres of Excellence in Durham, NC, USA and Guildford, Surrey, UK. For more information visit our website https://www.medpharm.com.

  • GB
  • 2018
    On CPhI since
  • 100 - 249
    Employees
Contact info

Products from MedPharm, Ltd

  • Manufacturing

    Product Manufacturing

    MedPharm supports the manufacture of toxicology testing, clinical trials and small scale commercial semi-solid and liquid products. 

    Our teams have significant experience in compounding, filling, packaging and labelling of all formulation types, ensuring they are ready for use in both clinical and commercial use around the globe. MedPharm supports clients with a seamless transition from Formulation Development through to Product Manufacturing, providing an end-to-end service that compliments the client's clinical research activity. 

    Our GMP accredited facilities are capable of manufacturing all topical formulation types including liquids and semi-solids in batch sizes up to 300 kg.

  • In Vitro Permeation Testing (IVPT)

    Product In Vitro Permeation Testing (IVPT)

    MedPharm offers its customers options for IVPT, including our unique MedFlux-HT® automated flow-through system or classic static Franz cells.

    IVPT is used to measure the permeation and penetration of a drug through tissue and is an essential tool for optimizing topical and transdermal formulations. A drug’s ability to permeate any tissue is dependent on the quantity and quality of the excipients used. IVPT cost-effectively provides a measure of performance of a product using human tissue and removes the uncertainty and ethics of working with animal models.

  • Formulation Development

    Product Formulation Development

    MedPharm has more than 20 years’ experience developing topical and transdermal formulations. We can begin as early as API screening and support pre-formulation activities, lead formulation selection, formulation optimization and reverse engineering. We have had a role in taking over 55 products to market. We partner with large and small companies in the cosmetic, OTC, Rx and medical device industries to de-risk their early development activities to develop formulations that meet target product profiles.

  • Drug Release Studies/In Vitro Release Testing (IVRT)

    Product Drug Release Studies/In Vitro Release Testing (IVRT)

    MedPharm leverages its 20 years of experience to help develop and validate IVRT methods for its clients. We successfully perform IVRT based on FDA and EMA guidelines and continue to influence how these methods are utilized in regulatory submissions.

    IVRT is the established method recognized by regulators and is commonly used for measuring the release of the active component(s) from semisolid products. Regulators are increasingly requiring validated IVRT methods as part of product release and stability specification.

  • Disease Activity Models/Tissue Culture

    Product Disease Activity Models/Tissue Culture

    MedPharm has developed proprietary models relevant for major disease areas such as psoriasis, atopic dermatitis, onychomycosis and continue to develop new ones through our dedicated innovation group. These sophisticated ex vivo experiments provide additional confidence to clients and their investors about how a product might behave in the clinic. Each of MedPharm’s models can be performed on the surface of the skin to model local topical delivery or ‘basolaterally’ from underneath to model systemic delivery, or allow the screening of a number of APIs.

    We can keep ex vivo skin biologically functioning in a laboratory for over 14 days to provide more options for looking at long term biological effects, such as repeat dosing. MedPharm has used these PK/PD models to directly help clients mitigate risks, inform API selection, assess new targets, and support marketing claims.

MedPharm, Ltd Resources